Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

TXNIP Regulates Peripheral Glucose Metabolism in Humans

Open access

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin secretion and action. Impaired glucose uptake in skeletal muscle is believed to be one of the earliest features in the natural history of T2DM, although underlying mechanisms remain obscure. METHODS AND FINDINGS: We combined human insulin/glucose clamp physiological studies with genome-wide expression profiling to identify thioredoxin interacting protein (TXNIP) as a gene whose expression is powerfully suppressed by insulin yet stimulated by glucose. In healthy individuals, its expression was inversely correlated to total body measures of glucose uptake. Forced expression of TXNIP in cultured adipocytes significantly reduced glucose uptake, while silencing with RNA interference in adipocytes and in skeletal muscle enhanced glucose uptake, confirming that the gene product is also a regulator of glucose uptake. TXNIP expression is consistently elevated in the muscle of prediabetics and diabetics, although in a panel of 4,450 Scandinavian individuals, we found no evidence for association between common genetic variation in the TXNIP gene and T2DM. CONCLUSIONS: TXNIP regulates both insulin-dependent and insulin-independent pathways of glucose uptake in human skeletal muscle. Combined with recent studies that have implicated TXNIP in pancreatic beta-cell glucose toxicity, our data suggest that TXNIP might play a key role in defective glucose homeostasis preceding overt T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0040158

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of Insulin on TXNIP, BCL6, and G0S2 Expression in Human Muscle In Vivo mRNA levels were measured in skeletal muscle biopsies of healthy individuals before and after the hyperinsulinemic euglycemic clamp for (A) TXNIP (n = 96, p < 1 × 10−14), (B) BCL6 (n = 90, p < 1 × 10−5), and (C) G0S2 (n = 95, p < 1 × 10−16). Levels were measured using real-time PCR and normalized to cyclophilin A mRNA. Inset shows the distribution of expression changes over individuals. p-Values refer to the Wilcoxon signed rank statistic.
Figure 1 Effects of Insulin on TXNIP, BCL6, and G0S2 Expression in Human Muscle In Vivo mRNA levels were measured in skeletal muscle biopsies of healthy individuals before and after the hyperinsulinemic euglycemic clamp for (A) TXNIP (n = 96, p < 1 × 10−14), (B) BCL6 (n = 90, p < 1 × 10−5), and (C) G0S2 (n = 95, p < 1 × 10−16). Levels were measured using real-time PCR and normalized to cyclophilin A mRNA. Inset shows the distribution of expression changes over individuals. p-Values refer to the Wilcoxon signed rank statistic.CC BY · PubMed Central
Figure 2 TXNIP Expression in Individuals with Diabetes or at Risk for Developing Diabetes (A) TXNIP expression levels from individuals with NGT, IGT, or T2DM, using data from our previously published microarray study [18]. * p < 0.02; ** p < 0.01, Mann-Whitney U-test. (B) TXNIP expression levels from NGT individuals with family history of T2DM (FH+) or without (FH−), as well as individuals with T2DM, using data from a previously published microarray study [27]. * p < 0.03, Mann-Whitney U-test.
Figure 2 TXNIP Expression in Individuals with Diabetes or at Risk for Developing Diabetes (A) TXNIP expression levels from individuals with NGT, IGT, or T2DM, using data from our previously published microarray study [18]. * p < 0.02; ** p < 0.01, Mann-Whitney U-test. (B) TXNIP expression levels from NGT individuals with family history of T2DM (FH+) or without (FH−), as well as individuals with T2DM, using data from a previously published microarray study [27]. * p < 0.03, Mann-Whitney U-test.CC BY · PubMed Central
Figure 3 Effects of Glucose and Insulin on the Expression of TXNIP in Cultured Human Adipocytes Human adipocytes were cultured in the presence (black bars) or absence (white bars) of 1 nM insulin at varying levels of glucose. Data are presented as mean ± standard deviation, normalized to the untreated control. * p < 0.05, Mann-Whitney U-test.
Figure 3 Effects of Glucose and Insulin on the Expression of TXNIP in Cultured Human Adipocytes Human adipocytes were cultured in the presence (black bars) or absence (white bars) of 1 nM insulin at varying levels of glucose. Data are presented as mean ± standard deviation, normalized to the untreated control. * p < 0.05, Mann-Whitney U-test.CC BY · PubMed Central
Figure 4 Insulin-Mediated Glucose Uptake Versus TXNIP Expression This relationship is shown for individuals with NGT, IGT, and T2DM. Linear regression parameters are indicated for each of the groups. Data are from our previously published microarray study [18].
Figure 4 Insulin-Mediated Glucose Uptake Versus TXNIP Expression This relationship is shown for individuals with NGT, IGT, and T2DM. Linear regression parameters are indicated for each of the groups. Data are from our previously published microarray study [18].CC BY · PubMed Central
Figure 5 Genetic Manipulation of TXNIP Expression Affects Both Basal and Insulin-Stimulated Glucose Uptake in Cultured Adipocytes and in Primary Skeletal Muscle Myocytes (A) Differentiated 3T3-L1 adipocytes cultured in 5.6 mM glucose were transduced with human TXNIP or empty virus particles and allowed to express the genes for 96 h. Cell lysates were immunoblotted using antibodies against TXNIP or actin. The exogenous viral human TXNIP protein is present as the more slowly migrating of the two bands. Glucose uptake with and without insulin was measured as described in Methods. Each data point represents an n = 4. * p < 0.02; ** p < 0.005. (B) Adipocytes cultured in 25 mM glucose were transfected with siRNA against TXNIP or with negative control siRNA and assayed 48 h posttransfection. Immunoblotting and glucose uptake are as above. n = 4 for each data point. * p < 0.02; ** p < 0.001. (C) Human skeletal muscle myoblasts obtained from biopsy were differentiated into myotubes in culture and transfected with siRNA against TXNIP or with negative control siRNA. Glucose uptake was measured at 72 h post-transfection with n = 4 for each data point. Each experiment was performed at least three times. * p < 0.01
Figure 5 Genetic Manipulation of TXNIP Expression Affects Both Basal and Insulin-Stimulated Glucose Uptake in Cultured Adipocytes and in Primary Skeletal Muscle Myocytes (A) Differentiated 3T3-L1 adipocytes cultured in 5.6 mM glucose were transduced with human TXNIP or empty virus particles and allowed to express the genes for 96 h. Cell lysates were immunoblotted using antibodies against TXNIP or actin. The exogenous viral human TXNIP protein is present as the more slowly migrating of the two bands. Glucose uptake with and without insulin was measured as described in Methods. Each data point represents an n = 4. * p < 0.02; ** p < 0.005. (B) Adipocytes cultured in 25 mM glucose were transfected with siRNA against TXNIP or with negative control siRNA and assayed 48 h posttransfection. Immunoblotting and glucose uptake are as above. n = 4 for each data point. * p < 0.02; ** p < 0.001. (C) Human skeletal muscle myoblasts obtained from biopsy were differentiated into myotubes in culture and transfected with siRNA against TXNIP or with negative control siRNA. Glucose uptake was measured at 72 h post-transfection with n = 4 for each data point. Each experiment was performed at least three times. * p < 0.01CC BY · PubMed Central
Figure 6 Pattern of Genetic Variation at the TXNIP Locus Linkage disequilibrium between SNPs was analyzed using Haploview [55], and D′ values were calculated with 95% confidence intervals. D′ plot for each square depicts the magnitude of linkage disequilibrium for a pair of markers, red indicates high D′ with high logarithm of odds (LOD) score, while white indicates low D′ with low LOD score, and blue indicates high D′ with low LOD score.
Figure 6 Pattern of Genetic Variation at the TXNIP Locus Linkage disequilibrium between SNPs was analyzed using Haploview [55], and D′ values were calculated with 95% confidence intervals. D′ plot for each square depicts the magnitude of linkage disequilibrium for a pair of markers, red indicates high D′ with high logarithm of odds (LOD) score, while white indicates low D′ with low LOD score, and blue indicates high D′ with low LOD score.CC BY · PubMed Central
Figure 7 Model of TXNIP Regulation and Action and Its Potential Role in the Pathogenesis of T2DM (A) Previous studies have shown that glucose induces the expression of TXNIP in a variety of cells and tissues. In this study we show that insulin suppresses the expression of TXNIP. Moreover, we have found that forced expression of TXNIP results in reduced glucose uptake, while inhibition of TXNIP enhances glucose uptake. These results suggest that TXNIP serves as a glucose- and insulin-sensitive homeostatic switch that regulates glucose uptake in the periphery. (B) Role of TXNIP in glucose toxicity in the β-cell and in impaired glucose uptake in the periphery. Insulin deficiency or hyperglycemia can increase TXNIP levels in muscle, resulting in impaired peripheral glucose uptake. The pancreatic β-cell is initially able to compensate by secreting more insulin, but eventually the β-cell compensation fails. The resulting hyperglycemia may then elevate pancreatic β-cell TXNIP expression, which can induce apoptosis [40]. The loss of β-cells, in turn, results in decreased insulin production that further exacerbates peripheral IGT. The vicious cycle would eventually spiral to T2DM.
Figure 7 Model of TXNIP Regulation and Action and Its Potential Role in the Pathogenesis of T2DM (A) Previous studies have shown that glucose induces the expression of TXNIP in a variety of cells and tissues. In this study we show that insulin suppresses the expression of TXNIP. Moreover, we have found that forced expression of TXNIP results in reduced glucose uptake, while inhibition of TXNIP enhances glucose uptake. These results suggest that TXNIP serves as a glucose- and insulin-sensitive homeostatic switch that regulates glucose uptake in the periphery. (B) Role of TXNIP in glucose toxicity in the β-cell and in impaired glucose uptake in the periphery. Insulin deficiency or hyperglycemia can increase TXNIP levels in muscle, resulting in impaired peripheral glucose uptake. The pancreatic β-cell is initially able to compensate by secreting more insulin, but eventually the β-cell compensation fails. The resulting hyperglycemia may then elevate pancreatic β-cell TXNIP expression, which can induce apoptosis [40]. The loss of β-cells, in turn, results in decreased insulin production that further exacerbates peripheral IGT. The vicious cycle would eventually spiral to T2DM.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 56

  1. Kahn, 1994, Diabetes, 43, 1066
  2. Eriksson, 1989, N Engl J Med, 321, 337
  3. Lyssenko, 2005, Diabetes, 54, 166
  4. Martin, 1992, Lancet, 340, 925
  5. Groop, 1996, Diabetes, 45, 1585
  6. Roden, 2005, Int J Obes, 2, S111
  7. Shulman, 2000, J Clin Invest, 106, 171
  8. Eriksson, 1990, Diabetologia, 33, 526
  9. Ling, 2004, J Clin Invest, 114, 1518
  10. Poulsen, 2005, Diabetes, 54, 275
  11. Chomczynski, 1987, Anal Biochem, 162, 156
  12. Golub, 1999, Science, 286, 531
  13. Wabitsch, 2001, Int J Obes Relat Metab Disord, 25, 8
  14. Al-Khalili, 2003, Cell Mol Life Sci, 60, 991
  15. Rubin, 1977, J Biol Chem, 252, 3554
  16. Al-Khalili, 2003, Biochem Biophys Res Commun, 307, 127
  17. Yoshioka, 2004, Circulation, 109, 2581
  18. Mootha, 2003, Nat Genet, 34, 267
  19. Ewing, 1998, Genome Res, 8, 186
  20. Ewing, 1998, Genome Res, 8, 175
  21. Staden, 1996, Mol Biotechnol, 5, 233
  22. de Bakker, 2005, Nat Genet, 37, 1217
  23. Florez, 2004, Diabetes, 53, 3313
  24. Purcell, 2003, Bioinformatics, 19, 149
  25. McClintick, 2006, BMC Bioinformatics, 7, 49
  26. Tusher, 2001, Proc Natl Acad Sci U S A, 98, 5116
  27. Patti, 2003, Proc Natl Acad Sci U S A, 100, 8466
  28. Yechoor, 2002, Proc Natl Acad Sci U S A, 99, 10587
  29. Yechoor, 2004, Proc Natl Acad Sci U S A, 101, 16525
  30. Zeger, 1986, Biometrics, 42, 121
  31. Zandbergen, 2005, Biochem J, 392, 313
  32. Phan, 2004, Nature, 432, 635
  33. Lee, 2003, Science, 302, 453
  34. Nishiyama, 1999, J Biol Chem, 274, 21645
  35. Shalev, 2002, Endocrinology, 143, 3695
  36. Hirota, 2002, J Biol Chem, 277, 44244
  37. Kobayashi, 2003, Kidney Int, 64, 1632
  38. Schulze, 2004, J Biol Chem, 279, 30369
  39. Hansen, 2004, Biochem Biophys Res Commun, 323, 685
  40. Minn, 2005, Endocrinology, 146, 2397
  41. Wolfrum, 2003, Proc Natl Acad Sci U S A, 100, 11624
  42. Elbein, 1999, Diabetes, 48, 1175
  43. Vionnet, 2000, Am J Hum Genet, 67, 1470
  44. Donnelly, 2004, J Nutr, 134, 1475
  45. Sheth, 2005, J Lipid Res, 46, 123
  46. Brownlee, 2001, Nature, 414, 813
  47. Houstis, 2006, Nature, 440, 944
  48. Petersen, 2003, Science, 300, 1140
  49. Wang, 2006, Oncogene, 25, 1903
  50. Han, 2003, Oncogene, 22, 4035
  51. DeFronzo, 2004, Med Clin North Am, 88
  52. Bonner-Weir, 2000, Trends Endocrinol Metab, 11, 375
  53. Poitout, 2002, Endocrinology, 143, 339
  54. Zierath, 2003, Best Pract Res Clin Endocrinol Metab, 17, 385
  55. Barrett, 2005, Bioinformatics, 21, 263
  56. Furuyama, 2000, Biochem J, 349, 629

Cited by

See all 499

Metadata

Authors
Parikh, H., Carlsson, E., Chutkow, W. A., Johansson, L. E., Storgaard, H., Poulsen, P., Saxena, R., Ladd, C., Schulze, P. C., Mazzini, M. J., Jensen, C. B., Krook, A., Björnholm, M., Tornqvist, H., Zierath, J. R., Ridderstråle, M., Altshuler, D., Lee, R. T., Vaag, A., Groop, L. C., & Mootha, V. K.
Affiliations
  • Lund University (SE)
  • Brigham and Women's Hospital (US)
  • Broad Institute (US)
  • Karolinska Institutet (SE)
  • Novo Nordisk (Denmark) (DK)
  • University of Helsinki (FI)
Corresponding author
  • Groop, Leif C
  • Mootha, Vamsi K
Venue
PLoS Medicine
Published
2007-05-01
Volume
4
Issue
5
Pages
e158
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2158951820
Cited by
495
References
57
Citations by year
2026: 10 · 2025: 17 · 2024: 24 · 2023: 41 · 2022: 35 · 2021: 39 · 2020: 34 · 2019: 22 · 2018: 29 · 2017: 21 · 2016: 29 · 2015: 29 · 2014: 23 · 2013: 28 · 2012: 31
FWCI
8.34
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • American Diabetes Association
  • Burroughs Wellcome Fund
  • Richard and Susan Smith Family Foundation
  • European Commission
  • Karolinska Institutet
  • Novo Nordisk
  • Vetenskapsrådet
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
TXNIP, type 2 diabetes, skeletal muscle glucose uptake, peripheral glucose metabolism, insulin signaling, adipocytes, prediabetes, glucose homeostasis, insulin-independent glucose uptake, genetic association
MeSH terms
Animals, Blood Glucose, Carrier Proteins, Cells, Cultured, Diabetes Mellitus, Type 2, DNA-Binding Proteins, Gene Expression Regulation, Homeostasis, Humans, Hypoglycemic Agents, Insulin, Promoter Regions, Genetic, Glucose Clamp Technique, Linkage Disequilibrium, Polymerase Chain Reaction, Adipocytes, Glucose Intolerance, Muscle, Skeletal, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Protein Array Analysis, Qb-SNARE Proteins, Proto-Oncogene Proteins c-bcl-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TXNIP Regulates Peripheral Glucose Metabolism in Humans. https://app.cochat.ai/papers/10.1371/journal.pmed.0040158
The paper
Parikh, H., Carlsson, E., Chutkow, W. A., Johansson, L. E., Storgaard, H., Poulsen, P., Saxena, R., Ladd, C., Schulze, P. C., Mazzini, M. J., Jensen, C. B., Krook, A., Björnholm, M., Tornqvist, H., Zierath, J. R., Ridderstråle, M., Altshuler, D., Lee, R. T., Vaag, A., . . . Mootha, V. K. (2007). TXNIP Regulates Peripheral Glucose Metabolism in Humans. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0040158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.